Vitamin D supplementation has a beneficial effect on cancerous patients, although it can influence the redox- and metal homeostasis. The aim of our investigation was to demonstrate the effect of vitamin D consumption on the redox- and metal homeostasis in prostate cancer, because of the recommended daily dose increased from 200 IU to 2000 IU in recent years in Hungary. Forty-three volunteers were involved in the study. The grouping was applied according to the clinical routine laboratory parameters (vitamin D) and the tumor markers (PSA, fPFA). Patients were divided into 5 groups: (A) patient control (N = 8), (B) patient control with vitamin D treatment (N = 9), (C) high-risk prostate cancer group (N = 6), (D) high-risk prostate cancer group with vitamin D treatment (N = 8) and (E) vitamin D treated cancerous group with androgen deprivation therapy (N = 11). The element concentrations were determined with ICP-OES. Among the redox parameters, free radical scavenging capacity and H-donating ability were determined with luminometry and spectrometry. Vitamin D treatment caused differences in the metal- and redox homeostasis in either patient control and cancerous groups. The concentration of Fe, Cr, and Pb significantly increased in the erythrocytes of prostate cancer patients. According to the higher scavenging capacity by vitamin D treatment, it seems that vitamin D helps to equilibrate the redox homeostasis that could affect the outcome of cancer positively. However, the tendency in the metal element status does not give a clear explanation of cancer's outcome, but the accumulation of Pb by vitamin D supplementation needs to be taken into more serious consideration in set terms of occupational diseases.
A kannabidiol kannabinoid-és szerotoninreceptor-antagonista, de a rimonabantra jellemző depresszív, illetve csök-kent inzulinérzékenység mellékhatásoktól mentesen mérsékelheti a hiperfágiát. Emellett, mint a peroxiszómaprolife-rátor-aktivált receptor-gamma-agonisták, segítheti az adipocyták differenciálódását. A kannabidiol immunmoduláns hatása miatt mérsékelheti a magas glükózszint indukálta atherosclerosis progresszióját. A metabolikus szindróma legveszélyesebb szövődményével, az elzáródásos kórképekkel szemben is hatásos. A kannabidiol gyenge receptorkötődése révén csak az adjuváns terápia része lehet. A citokróm P450 enzimrendszert gátló hatása szintén óvatos-ságra int, azonban a kannabidiol kiegészítő alkalmazása gyenge mellékhatásprofi lja miatt hasznossá válhat. Orv. Hetil., 2012, 153, 499-504. Kulcsszavak: kannabidiol, metabolikus szindróma, lipidmetabolizmus, ischaemiaThe potential use of cannabidiol in the therapy of metabolic syndrome Cannabidiol, a cannabinoid and serotonin receptor antagonist, may alleviate hyperphagia without the side effects of rimonabant (for example depression and reduced insulin sensitivity). Similar to the peroxisome proliferator-activated receptor-gamma agonists, it may also help the differentation of adipocytes. Cannabidiol has an immunomodulant effect as well that helps lessen the progression of atherosclerosis induced by high glucose level. It may also be effective in fi ghting ischaemic diseases, the most harmful complications of metabolic syndrome. However, it can only be administered as an adjuvant therapy because of its low binding potency, and its inhibiting effect of cytochrome P450 enzymes should also be considered. Nevertheless,,it may be benefi cially used in adjuvent therapy because of its weak side-effect profi le. Orv. Hetil., 2012, 153, 499-504. Keywords: cannabidiol, metabolic syndrome, lipid metabolism, ischemia (Beérkezett: 2011. december 14.; elfogadva: 2012. január 15.) Rövidítések CB-R = kannabinoidreceptor; CBD = kannabidiol, GPR55 = G-protein-kapcsolt receptor; 5-HT 1A = 1A típusú szerotoninreceptor; HMGB1 = (high mobility group box1) nagy mozgékonyságú csoport: citokinszerű mediátor; iNOS = indukálható nitrogén-monoxid-szintáz; MPO = mieloperoxidáz; NADPH = nikotinamid-adenin-dinukleotid-foszfát redukált forma; NF-кB = nukleáris faktor кB; p38 MAPK = mitogén-aktivált proteinkináz; PPAR-gamma = (peroxisome proliferator-activated receptor gamma) peroxiszómaproliferátor-aktivált r eceptor-gamma; ROS = (reactive oxygen substances) reaktív oxigéngyökök; STAT = (signal transducer and activator of transcription) szignalizációs transzducer és transzkripcióaktivátor; TNF-alfa = tumornekrózis-faktor-alfa; THC = d9-tetrahidro-kannabinol; TRP = tranziens receptorpotenciál A kannabidiol a kender nem pszichoaktív fő ható-anyaga, sokrétű farmakológiai hatásából több előnyös lehet a metabolikus szindróma terápiájában.A metabolikus szindróma összetettségénél fogva nehezen kezelhető gyógyszerrel, mert egyaránt csök-kenteni kell a vérnyomást, a vércukor-, a triglicer...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.